| |
View Points |
|
| |
|
|
|
| |
|
Cancer Risks Estimated for BRCA1 and BRCA2 Carrier Patients
Mavaddat N, Peock S, Frost D, et al.J. Natl. Cancer Inst. 2013 Apr 29;[EPub Ahead of Print]. |
|
| |
|
Management of Breast-Cancer Patients with Sentinel-Node Micrometastases
Benson JR |
|
| |
|
New DCIS Score That Quantifies Risk of AnotherIspilateral Breast Event
J. Natl. Cancer Inst. 2013 May 02;[EPub Ahead of Print], LJ Solin, R Gray, FL Baehner, et al |
|
| |
|
Endocrine Therapy Adverse Events Predict Survival
J. Clin. Oncol. 2013 Apr 22;[EPub Ahead of Print], DB Fontein, C Seynaeve, P Hadji, et al
|
|
| |
|
|
|
| |
News |
|
| |
|
|
|
| |
|
Smaller Margins Too Close for Comfort in Breast Cancer
OsterweilN. IMNG Medical Media, 2013 Apr 25. |
|
| |
|
Intraperitoneal Chemo Superior in Low-Volume Residual Ovarian Cancer
London S, et al. IMNG Medical Media, 2013 Apr 30. |
|
| |
|
Timely Palliative Consult Affects End-of-Life Care in Gynecologic Cancer Patients
London S. IMNG Medical Media, 2013 Apr 30, S London |
|
| |
|
|
|
| |
Journal Scan |
|
| |
|
|
|
| |
|
A phase II study of modified dose-dense Paclitaxel and every 4-week carboplatin for the treatment of advanced-stage primary epithelial ovarian, fallopian tube, or peritoneal carcinoma.
Abaid LN, Micha JP, Rettenmaier MA, et al. Cancer ChemotherPharmacol. 2013 May 10. [Epub ahead of print]. |
|
| |
|
A feasibility study on maintenance of Docetaxel after Paclitaxel-Carboplatin chemotherapy in patients with advanced ovarian cancer.
Isonishi S, Suzuki M, Nagano H, et al. J GynecolOncol. 2013 Apr;24(2):154-9. |
|
| |
|
Combination of GHRH antagonists and docetaxel shows experimental effectiveness for the treatment of triple-negative breast cancers.
Seitz S, Rick FG, Schally AV, et al. Oncol Rep. 2013 Apr 29. doi: 10.3892/or.2013.2435. [Epub ahead of print] |
|
| |
|
|
|
| |
Review Articles |
|
| |
|
|
|
| |
|
Review of Role Signaling Pathways of HER2, EGFR/PI3K/Akt Play in Post-Irradiation Survival
Kaidar-Persona O, Laib O, Kutena A, et al. Breast 2013 Apr 30;[EPub Ahead of Print]. |
|
| |
|
The role of adjuvant therapy in endometrial cancer.
Kupets R and Le T. J ObstetGynaecol Can. 2013 Apr;35(4):375-6. |
|
| |
|
Review of Landmark Trials Guiding Surgical Management of Breast Cancer
Black DM andMittendorf EA. Surg. Oncol.Clin.N. Am. 2013 Apr 19;93(2)501-518. |
|
| |
|
|
|
|
